HOME >> BIOLOGY >> NEWS
The future of HIV therapeutics is brightening, according to Gladstone Institutes Director

Recent discoveries about the way that HIV infects cells are propelling the development of a broad spectrum of promising new antiviral drugs, according to an invited commentary on the topic in the current issue of Nature Immunology (August 27, 2004).

The assessment is made by Gladstone Institute of Virology and Immunology (GIVI) Director Warner Greene, MD, PhD, who also serves as professor of medicine, microbiology and immunology at the University of California, San Francisco.

In the piece, Greene points out that basic research on HIV, a relatively simple pathogen with only nine genes encoding 15 proteins, are leading to compelling new therapies that deny the initial entry of HIV into its cellular host. In addition, fast-moving research of naturally occurring factors with potent antiviral properties is opening the way for future development of an entirely new class of anti-HIV drugs.

New agents that block the first step in HIV's life cycle, the entry of the HIV virion (a single virus particle) into host CD4 T-cells, are quickly moving down the drug development pipeline. Chief among these therapeutics are drugs known as chemokine receptor antagonists that interfere with HIV's ability to bind to CCR5, one of two key surface receptors needed for the virus to penetrate the cell. Although these HIV co-receptors were identified only seven years ago, basic studies performed by both GIVI investigators and scientists around the world have helped accelerate clinical development of CCR5 antagonists as a new class of anti-HIV drugs. Several major pharmaceutical companies are now racing to the finishing line.

These advances address but one of the three steps required for successful entry of the HIV virus. The other two steps involve the attachment of HIV virions to surface CD4 receptors and the final fusion of virions to target cells. These steps are also being targeted with new antiviral drugs. Combinations of inhibitors acting at each o
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-695-3833
University of California - San Francisco
27-Aug-2004


Page: 1 2 3

Related biology news :

1. New fruitfly model of diabetes has future implications for pancreatic cell transplantation
2. Charting the future in prostate cancer care: A call to action
3. Sandia experiments may reduce possibility of future water wars
4. Will a reduction in military spending improve our environmental future?
5. Engineering endurance: The future of the Olympics?
6. The future of nanotechnology
7. Chemoradioimmunotherapy for advanced breast cancer: hope for the future?
8. Endometriosis: Could angiostatic therapy be the new treatment of the future?
9. Plants for the future: A European vision for plant biotechnology towards 2025
10. Plant pathologists to discuss the future of organic farming
11. Stem cells commit to a future of fat with one signal

Post Your Comments:
(Date:7/29/2014)... New research from scientists at the University of Kent ... inside cells are regulated a breakthrough that could ... A team from Kent,s School of Biosciences uncovered the ... within cells known as actin filaments are ... these actin filaments appear to completely stable, providing a ...
(Date:7/29/2014)... breaking new book that brings together two of the ... the profile of insect fossils through stunning photographs and ... and James E Jepson, details the incredible preservation and ... the scene for what these remarkable fossils can tell ... the future of our planet. Like the mosquito in ...
(Date:7/28/2014)... U.S. Food and Drug Administration (FDA) for other purposes ... inside human cells, including those that cause Legionnaires, disease, ... mBio , the online open-access journal of the ... identifying non-antibiotic drugs that could one day help curb ... the list inhibit the growth of at least three ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2New route to identify drugs that can fight bacterial infections 2
(Date:7/29/2014)... (PRWEB) July 29, 2014 TransVac Solutions, ... linen collection and transport solutions for hospitals, will be ... Healthcare Engineering (ASHE) Annual Conference & Technical Exhibition Aug. ... present its technology for making hospitals cleaner, reducing infection ... over the hospital’s life cycle. Staff will be ...
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready ... The Innovation Center @3401 , a collaborative effort of ... Center to help attract and nurture start-up businesses in ... , The Innovation Center @3401 (ic@3401), which ... is the new home of DreamIt Ventures and ...
(Date:7/29/2014)... July 29, 2014  Sigma-Aldrich Corporation (NASDAQ: ... use, increased its investment in Green Chemistry and donated ... world last year, the Company announced Monday in its ... Changed the World? The report comes ... for being a responsible corporate citizen, including recognition for ...
(Date:7/29/2014)... July 29, 2014 Quorum Review ... has been awarded accreditation by the International ... its Lean Six Sigma Deployment Program. The citation ... improve performance. , Quorum’s Lean Six Sigma program ... Deployment Program designation. The designation is a public ...
Breaking Biology Technology:TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3
Cached News: